Dynavax Technologies has dosed the first subject in a Phase I/II clinical trial of Z-1018, an investigational vaccine aimed at preventing shingles, also known as herpes zoster.
The active-controlled, randomised, dose escalation, multi-centre trial is anticipated to enrol around 440 healthy adults…
[ad_2]
Source link
